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Summary A simple method for the rapid expansion of human CD4+ T cells with both helper and killer
functions was established. CD4+ T cells separated from peripheral blood mononuclear cells using
immunomagnetic beads were stimulated with immobilised OKT-3 monoclonal antibody (mAb) plus recom-
binant interleukin 2 (rIL-2) in 96 well culture plates. After 6 day-culture, the CD4+ T cells were restimulated
by immobilised OKT-3 mAb for an additional 24 h, then inoculated into concentrated rotary-tissue culture
bag and cultured for further 9 days. This procedure yielded a 3000-fold increase in cell number (about
3-5 x109 per bag). Most of the cells (over 96%) continued to express CD4+ antigen and retained their
capacity to produce IL-2. The activated CD4+ T cells showed marked cytotoxicity against Fc receptor positive
tumour cells in the presence of OKT-3 mAb. Moreover, we succeeded in a specific targeting of the expanded
CD4+ helper/killer T cells to c-erbB-2 positive tumour cells by means of anti-CD3 x anti-c-erbB-2 bispecific
antibody. These results suggested that our established simple system will be available for the expansion of
large number of CD4+ helper/killer T cells which may provide an efficient strategy for adoptive tumour
immunotherapy.
Recent work has demonstrated that introducing 'local help'
at the tumour site is an important goal for the induction of
anti-tumour activity in tumour-bearing hosts (Nishimura et
al., 1988; Fearon et al., 1990; Bubenik et al., 1990). It has
been demonstrated that adoptive tumour immunotherapy
using lymphokine-activated killer (LAK)5 cells and cytotoxic
T lymphocytes was effective in animal and clinical systems
(Cheever et al., 1982; Mule et al., 1984; Nishimura et al.,
1986; Rosenberg et al., 1985). However, adoptive immuno-
therapy might give better results if helper T cells were trans-
ferred into the locality of the tumour together with killer
cells. To develop this helper/killer therapy, it is necessary first
to establish a large-scale culture system for human CD4+ T
cells.
It has been demonstrated that culture of peripheral blood
mononuclear cells (PBMC) in the presence of interleukin 2
(IL-2) caused the predominant growth of CD8+ T cells
(Gullberg et al., 1983; Taylor et al., 1985) and the selective in
vitro growth of CD4+ T cells in the presence of IL-2 has
been considered to be difficult. The different IL-2 respon-
siveness of CD8+ and CD4+ T cells was demonstrated to be
derived from their differential expression of p75 IL-2 receptor
(IL-2R) (Nakamura et al., 1991; Ohashi et al., 1989).
Recently, however, we demonstrated that stimulation of
FACStar-sorted CD4+ T cells with immobilised OKT-3
monoclonal antibody (mAb) induced p75 IL-2R expression
and IL-2 responsiveness of CD4+ T cells. Moreover, CD4+ T
cells have demonstrated to display both IL-2 producing
activity and bispecific antibody-directed antitumour activity
(Nishimura et al., 1991, 1992a). Therefore, CD4+ helper/
killer T cells could be available for adoptive tumour
immunotherapy if we could develop a more simple method
for the isolation and expansion of CD4+ T cells.
In this paper, we describe a simple method for the genera-
tion and expansion of CD4+ T cells with both helper and
killer functions in the presence of immobilised anti-CD3
mAb plus IL-2. The large-scale expansion of activated CD4+
helper/killer T cells was achieved using a concentrated rotary
tissue-culture (CRTC) bag. We also investigated in vitro
targeting of the CD4+ helper/killer T cells by means of
anti-CD3 x anti-c-erbB-2 bispecific antibody (BsAb).
Materials and methods
Monoclonal antibodies
OKT-3 (anti-CD3), OKT-4 (anti-CD4) and OKT-8 (anti-
CD8) mAbs were purchased from American Type Culture
Collection (Rockville, Mayland, USA). The mAbs against
CD45RA (Leu-18) and CD45RO (Leu-45RO) were pur-
chased from Becton Dickinson (Mountain View, CA), and
mAb against CDw29 (4B4) from Coulter Electronics
(Hialeah, FL). SER-4 mAb recognising p185 kD extracellular
domain of c-erbB-2 gene product (kindly donated by Dr T.
Masuko, Tohoku University Pharmaceutical Institute, Sendai
980, Japan) was produced from the mice immunised with
SK-BR-3 breast cancer cells as described previously (Masuko
et al., 1989).
Separation ofCD4+ T cells by immunomagnetic beads
Human PBMC were isolated from two breast cancer patients
and two colon cancer patients by Ficoll/Conray (1.077 g
ml-') gradient centrifugation. The cells were incubated at
37°C for 30 min on a nylon-wool column (Wako Pure
Chemicals, Osaka, Japan) to remove macrophages and B
lymphocytes. Nylon-passed T enriched cells (107 cells) were
incubated with 10 jig of OKT-4 mAb on ice for 15 min. The
cells were washed twice with RPMI-1640 medium containing
10% human AB serum. The separation of CD4+ T cells was
performed by a positive selection technique (Gaudernack et
al., 1986) using sheep anti-mouse IgG-coated
immunomagnetic beads (Dynabeads M-450, Dynal Inc.,
Oslo, Norway). Dynabeads were washed three times with
RPMI-1640 medium containing 10% human AB serum to
remove sodium azide. The OKT-4 mAb-treated cell pellets
(I0O) were mixed with Dynabeads (4 x 107) at 4°C for 30 min
with gentle shaking every 5 min. CD4+ T cells bound to the
Dynabeads were recovered with a Dynal MPC-1 magnet
(Dynal Inc.). The purity of CD4+ T cells in recovered cells
was over 98%. The isolated CD4+ T cells consisted of 46%
of CD45RO and 54% of CD45RA.
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Generation and expansion ofCD4+ helper/killer T cells by
culture with immobilised OKT-3 mAbplus recombinant human
IL-2 (rIL-2)
CD4+ T cells (1-3 x 106) were isolated from 20 ml of blood
of tumour patient using Dynabeads as described above. The
CD4+ T cells bound to Dynabeads were suspended in
RPMI-1640 medium containing 10% AB human serum,
2 mm glutamine, 1 mM sodium pyruvate, 25 mM Hepes
buffer, 100 U ml-' of penicillin and 00figml1' of strepto-
mycin. OKT-3 mAb was immobilised in 96 well flat-
bottomed culture plates by incubating 100 lI of OKT-3 mAb
(5 gig ml-') in each well for 2 h at 37C. Then, CD4+ T cells
(2-3 x I05 cells) were added to each well and incubated at
37°C in the presence of 2000 U ml-' of rIL-2. After 3 day-
culture, Dynabeads were detached from the cells by vigorous
pipetting and were eliminated from the culture using a Dynal
magnet. Then, the cells were further expanded in 96 well
plate in the presence of 2000 U ml ' of IL-2. The activated
CD4+ cells increased to 108 levels in cell number using 96
well-plates at 6-7 days after the initiation of culture. A
large-scale expansion of CD4+ T cells were further carried
out using concentrated rotary tissue-culture (CRTC) bags
(CC5100 E; Kawasumi Laboratories Inc., Tokyo, Japan)
(Nakamura et al., 1989; Noto et al., 1989). As illustrated in
Figure 1, the CRTC bag has two compartments, an inner
compartment separated from an outer compartment by a
semipermeable membrane (Union Carbide Corp., pore
size = 2.4 nm). At 6-7 days after the initiation ofculture, the
CD4+ helper/killer T cells were restimulated with immobil-
ised OKT-3 mAb for 24 h at 37°C using 96 well plates
(3--5 x 105 cells/well). Then, the activated cells (2 x 108) were
harvested, resuspended in 500 ml of RPMI medium contain-
ing 20% human AB serum and 2000 U ml-' of rIL-2, and
were poured into an inner compartment of the CRTC bag.
E E
Figure 1 Diagram of concentrate rotary tissue-culture (CRTC)
bag. A, Outlet of inner space; B, Inner bag (semipermeable
membrane), C, Protection net; D, Outer bag; E, Outlet of outer
space.
Two litres of RPMI medium were placed into an outer
compartment. The bag was rotated at an angle of 450
between 0.5 and 1.0 r.p.m., in a 37C incubator for 8-9 days
as described previously (Nakamura et al., 1989).
Flow cytometry
The analysis of cell surface markers was carried out by
FACScan (Becton Dickinson) using the Consort 30 program.
The detailed procedure for staining was described in a
previous paper (Nishimura et al., 1990). Fluorescence data
were collected with logarithmic amplification. For each sam-
ple, data from 10,000 volume-gated viable cells were col-
lected.
Theproduction ofIL-2 by expanded CD4+ helper/killer T cells
The production of IL-2 was determined using IL-2-dependent
murine T cell clone, HT-2. CD4+ T cells (2 x 105) were
stimulated with 20 ng ml' of phorbol 12-myristate 13-
acetate (PMA, Sigma, St. Louis, MO), 500 ngml-' of cal-
cium ionophore (A23187, Sigma), PMA plus A23187, OKT-3
mAb-coated Dynabeads (8 x 105) or PMA plus OKT-3 mAb-
coated Dynabeads for 24 h at 37°C. After incubation, the
culture supernatants were harvested and their IL-2 activity
were measured using HT-2 cells. Briefly, 104 HT-2 cells/well
were cultured with IL-2 samples or standard IL-2 for 20 h,
then pulsed with 3H-TdR (0.5giCi/well) for 4h. The radio-
activity of the labeled cells was measured by the usual liquid
scintillation technique (Chiba et al., 1985). As demonstrated
previously (Maeda et al., 1988), human IL-2, but not human
IL-4, could stimulate the proliferation of mouse T cell lines.
Therefore, only human IL-2 activity could be determined
using HT-2 cells.
Preparation ofbispecific antibody (BsAb) containing anti-CD3
and anti-c-erbB-2
For the targeting of CD4+ helper/killer T cells, BsAb con-
taining anti-CD3 and anti-c-erbB-2 were prepared. OKT-3
mAb was chemically conjugated with anti-c-erbB-2 mAb
(SER-4) by incubation with a thiol activating reagent 5,
5'-dithio-bis-2-nitrobenzoic acid (DTNB, Sigma, St. Louis
MO) as described previously (Nitta et al., 1990a; Nitta et al.,
1990b; Nishimura et al., 1991).
Cytotoxicity assay
The cytotoxicity of the expanded CD4+ T cells was deter-
mined by 4 h-5'Cr release assay as described previously
(Nishimura et al., 1987). Briefly, 2.5 x 103 5'Cr-labeled target
cells were incubated with 5 x 104 effector cells in the presence
or absence of OKT-3 mAb (5jig ml-') or BsAb (0.5gg ml-')
for 4 h. After 4 h, 100gil of culture supernatants were
removed to determine the cytotoxicity of effector cells. Per-
cent cytotoxicity was determined by the following formula;
% cytotoxicity = 5Cr release with effector cells - spon-
taneous 5'Cr release/51Cr release with 0.1 N HCI - spon-
taneous 5'Cr release. OKT-3, OKT-4 and OKT-8 hybridoma
cell, Fc-receptor (FcR) positive Daudi (Barkitt lymphoma),
K562 (preerythroblastic cell), U937 (monocyte-related cell)
and FcR negative IMR-32 glioma cells were used as target
cells. NIH-3T3, SVII (NIH-3T3 transfected with normal c-
erbB-2 gene), A4- 15 (NIH-3T3 cells transfected with
mutated c-erbB-2 gene), RAScD (NIH-3T3 cells transfected
with EJ ras gene) and KATOIII (human gastric cancer) were
used for the targeting of CD4+ helper/killer T cells. The
oncogene transfectants were kindly donated by Dr T.
Yamamoto (Tokyo University School of Medicine, Tokyo,
Japan) (Masuko et al., 1989).22 Y. NAKAMURA et al.
Results
Proliferation offreshly isolated human CD4+ T cells by
immobilised OKT-3 mAb plus rIL-2
Human CD4+ T cells which were freshly isolated from
PBMC of breast cancer patient using FACStar or Dynabeads
were plated into 96 well plates and their proliferative res-
ponses to IL-2, immobilised OKT-3 mAb or IL-2 plus
immobilised OKT-3 mAb were determined. As shown in
Figure 2, FACStar-sorted CD4+ T cells did not respond to
IL-2 or immobilised OKT-3 mAb alone. However, they
showed a marked proliferative response in the presence of
IL-2 plus immobilised OKT-3 mAb. In contrast to FACStar-
sorted CD4+ T cells, CD4+ T cells separated with
Dynabeads showed a marked responsiveness to immobilised
OKT-3 mAb alone. The OKT-3 mAb-induced proliferation
of Dynabeads-separated CD4+ T cells was further enhanced
by adding rIL-2 into the culture. It was also notable that
Dynabeads-separated CD4+ T cells revealed higher level of
proliferative responses to immobilised OKT-3 mAb plus rIL-
2 than CD4+ T cells isolated by FACStar.
Large-scale expansion ofCD4+ T cells
CD4+ T cells were isolated from 20 ml of blood of two
breast and two colon cancer patients by Dynabeads. Then,
the separated CD4+ T cells (1-3 x 106) were cultured with
immobilised OKT-3 mAb plus rIL-2. After 6-7 day-culture,
the activated CD4+ T cells (2 x 108) were restimulated with
immobilised OKT-3 mAb and inoculated into CRTC bags.
As illustrated in Figure 3, CD4+ T cells showed rapid growth
in CRTC bag in the presence of rIL-2, and their numbers
increased to over 3-5 x 109 within 14-16 days. This large-
scale culture yielded an approximate 3000-fold increase in cell
numbers after 16 day-culture.
Helper and killerfunctions ofthe expanded CD4+ T cells
The functions of the expanded CD4+ T cells were examined
after 16 days of culture. The cells produced large amounts of
IL-2 after stimulation with PMA plus A23187, but not with
either alone (Table I). The OKT-3 mAb-coated Dynabeads
also stimulated CD4+ T cells to produce IL-2. Addition of
PMA into the culture enhanced OKT-3 mAb-induced IL-2
production of CD4+ T cells. Thus, the CD4+ T cells
expanded by our culture system retained their ability to
produce IL-2, which was triggered through T cell receptor-
Cell
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Figure 2 Proliferative responses of human CD4+ T cells isolated
with FACStar or Dynabeads. Human CD4+ T cells were isolated
using FACStar (open bars) or Dynabeads (hatched bars) as
described in Materials and methods. The isolated CD4+ T cells
were cultured in 96 well plates with medium, 2000 U ml- ' of
rIL-2, immobilised OKT-3 mAb or immobilised OKT-3 mAb
plus rIL-2. The proliferative responses of the cells were deter-
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Figure 3 The growth curve of CD4+ helper/killer cells in a
CRTC bag. CD4+ T cells were isolated from colon cancer
patients (No 1 and No 3) or breast cancer patients (No 2 and No
4) using Dynabeads. The isolated CD4+ T cells (1-3 x 106) were
cultured with immobilised OKT-3 mAb plus IL-2. At 3 days after
culture, Dynabeads were removed from the culture using Dynal
magnet. When the cells were increased to 1-2 x 108 in cell
number (6-7 days after culture), the cells were restimulated with
immobilised OKT-3 mAb in 96 well plates for 24h, and then
inoculated into CRTC bag. The cell numbers in CRTC bag was
counted until 16 days after the initiation of culture.
Table I Production of IL-2 by expanded CD4+ helper/killer T cells
Patient No.
Stimulator 1 2 3 4
None <2 <2 <2 <2
PMA alone <2 <2 <2 <2
A23187 alone <2 <2 <2 <2
PMA + A23187 64.0 73.5 73.8 79.0
OKT-3 mAb bound 58.0 46.0 58.0 20.0
Dynabeads
OKT-3 mAb bound 68.0 56.0 80.0 78.6
Dynabeads + PMA
At the end of culture, the cells were stimulated with various
stimulators and their ability to produce IL-2 was measured using
IL-2-dependent HT-2cells, asdescribed in Materials andmethods. IL-2
activity is expressed by a unit per 2 x 106 cells. The unit of IL-2 was
defined by thereciprocal dilution ofIL-2 samplethatevoked50% ofthe
maximum proliferation(c.p.m.)ofHT-2cells. Recombinant IL-2which
unit was already defined by NIH standard sample was used for the
determination of IL-2 unit of sample.
CD3 complex or intracellular signals. The IL-2 activity in the
culture supernatants was completely neutralised by anti-IL-2
polyclonal antibody (data not shown).
The killer functions of the activated CD4+ T cells were
also determined. As shown in Figure 4, the activated CD4+
T cells lysed anti-CD3 mAb-producing hybridoma cells, but
not anti-CD4 or anti-CD8 mAb-producing hybridoma cells.
These results indicated that CD4+ T cells lysed hybridoma
cells in anti-CD3 mAb-dependent manner. Therefore, we also
examined the cytotoxicity of expanded CD4+ T cells against
various tumour cell lines in the presence or absence of OKT-
3 mAb. OKT-3 mAb-induced cytotoxicity has been demon-
strated to be only achieved by direct binding of the FcR on
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Figure 4 OKT-3 mAb-induced cytotoxicity against a variety of tumour cells by expanded CD4+ helper/killer T cells. CD4+
helper/killer cells were induced from four different tumour patients described in the legend of Figure 3. Cytotoxicity against various
tumour cells was measured by a 5'Cr release assay in the presence (hatched bars) or absence (open bars) of 5 fg ml-' of OKT-3
mAb. Effector to target cell ratio was 20: 1. No exogenous OKT-3 mAb was added into the culture when hybridoma cells (OKT-3,
OKT-4, OKT-8) were used as target cells, but each hybridoma cell could produce anti-CD3, anti-CD4 or anti-CD8 mAb,
respectively, during cytotoxicity assay.
target cells to Fc posion of OKT-3 mAb (Seventer et al.,
1987). Judging from their sensibility to anti-CD3 mAb
induced cytotoxicity, K562, Daudi and U937 cells, but not
IMR-32 glioma cells, have demonstrated to express FcR on
their cell surface (Seventer et al., 1987 and Nitta et al.,
1990b). Inconsistent with these results, the activated CD4+ T
cells lysed K562. Daudi and U937 cells in the presence of
OKT-3 mAb. However, IMR-32 glioma cells were resistant
to OKT-3 mAb-induced cytotoxicity of CD4+ T cells (Figure
4). The resistance of IMR-32 against CD4+ T cells-mediated
killing was not derived from their unresponsiveness to killing
because IMR-32 were lysed by CD4+ T cells by adding
anti-CD3 x anti-glioma bispecific antibody (Nishimura et al.,
1992a). From these results, it was demonstrated that the
activated CD4+ T cells with immobilised OKT-3 mAb plus
rIL-2 had both helper and killer functions. Such killer func-
tion of CD4+ T cells were not detected in freshly isolated
CD4+ T cells as reported previously (Nishimura et al.,
1992a).
In vitro targeting ofthe expanded CD4+ helper/killer T cells
by using anti-CD3 x anti-c-erbB-2 BsAb
We tried in vitro targeting of the expanded CD4+ helper/
killer T cells to various kinds of tumour cell lines by using
anti-CD3 x anti-c-erB-2 BsAb. As shown in Figure 5, the
expanded CD4+ helper/killer T cells showed slight cyto-
toxicity against tumour cell lines in the absence of BsAb.
However, addition of BsAb into the culture resulted in the
induction of a strong cytotoxicity against c-erbB-2 transfec-
tants (A4-15 and SV- 1) and c-erbB-2 expressing tumour
cell line, KATOIII. In contrast, native NIH-3T3, EJ ras-
transfectant (RAScD) or c-erbB-2 negative tumour cell line,
Daudi B lymphoma cells were resistant to CD4+ helper/killer
cells even in the presence of BsAb. Thus, these results
indicated that it was possible to develop an efficient strategy
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Figure 5 Specific in vitro targeting of expanded CD4+ helper/killer T cells by using anti-CD3 x anti-c-erbB-2 BsAb. CD4+
helper/killer cells were induced from four different tumour patients described in the legend of Figure 3. The cytotoxicity was
determined by 4 h-5"Cr release assay in the presence (hatched bars) or absence (open bars) of anti-c-erbB-2 BsAb (0.5 jAg ml-').
Effector to target cell ratio was 20:1. Oncogene transfectant (SVI 1, A4-15, RAScD) and human tumour cells (KATOIII, Daudi B
lymphoma) were used as target cells. The cell surface expression of c-erbB-2 was determined by FACScan.
Flow cytometry analysis ofCD4+ helper/killer T cells
The surface markers of the expanded CD4+ helper/killer T
cells were analysed by flow-cytometry technique at the end of
culture. As shown in Table II, the activated cells continued
to express CD4 antigen. Moreover, it was demonstrated that
most of the CD4+ T cells expressed CDw29 and CD45RO,
though a small percentage of the cells also expressed
CD45RA antigen. These results indicated that stimulation of
CD4+ T cells with OKT-3 mAb and rIL-2 resulted in a
selective expansion of helper-inducer subpopulation of CD4+
T cells.
Table II Cell surface markers of expanded CD4+ helper/killer T
cells
Patient
No. CD4/CD80 CD4, CDw29b CD45RO/CD45RAC
1 98/1 99 96/1
2 95/2 97 89/10
3 97/1 98 90/6
4 96/1 99 98/3
aPercentage ofcellsexpressingeitherCD4 orCD8 wasdetermined by
flow cytometric analysis as described in Materials and methods.
bPercentage ofcells expressing both CD4 and CDw29. cPercentage of
cells expressing either CD45RO or CD45RA.
Discussion
This paper presents an efficient method for the large-scale
culture of human CD4+ helper/killer T cells from Dyna-
beads-isolated CD4+ T cells. As reported previously
(Nakamura et al., 1991), freshly isolated CD4+ T cells by
FACStar can not respond to rIL-2 because of their lack of
p75 IL-2R expression. However, stimulation of CD4+ T cells
with immobilised OKT-3 mAb induced p75 IL-2R expression
and their marked proliferative response to rIL-2 (Nishimura
et al., 1992a). As shown in Figure 2, FACStar sorted CD4+
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immobilised OKT-3 mAb in the absence of IL-2. In contrast,
CD4+ T cells isolated with Dynabeads revealed a significant
proliferative response to immobilised OKT-3 mAb in the
absence of rIL-2 (Figure 2). Crosslinking ofcell-bound OKT-
4 mAb with anti-mouse Ig coupled-Dynabeads resulted in the
conversion of OKT-4 mAb from soluble to solid phase.
Therefore, Dynabeads-separated CD4+ T cells may be
activated through both CD3 and CD4 molecules. Our results
are supported by the results of Emmrich et al. (1987) who
reported that double immobilisation of anti-CD3 and anti-
CD4 induced higher proliferation of CD4+ T cells compared
with single immobilisation of anti-CD3 mAb. Thus, the
separation procedure of CD4+ T cells using Dynabeads has
two advantages over a method using a cell sorter; (1) The
procedure is simple and rapid; (2) Dynabeads preparation
causes augmented proliferation of CD4+ T cells against
immobilised anti-CD3 plus IL-2.
As reported previously (Noto et al., 1989), we demon-
strated that large numbers of LAK cells could be expanded
in CRTC culture bag which was developed by us. We have
now shown that the CRTC culture bag is suitable for the
expansion of CD4+ T cells. It has been reported that culture
of PBMC by culture plate in the presence of rIL-2 alone
yielded about 10-20 fold increase in cell numbers, and cul-
ture with immobilised anti-CD3 mAb plus rIL-2 yielded a
500 fold increase in cell numbers (Anderson et al., 1988). We
also demonstrated that culture of isolated CD4+ T cells with
immobilised OKT-3 mAb plus rIL-2 caused 200 fold increase
from 106 to 2 x 108 cells in 6-7 days culture. As previously
reported by us, CD4+ T cells could be expanded for over a
month in a split culture using 96 well plate. Because CD4+ T
cells grew in 96 well plates at the same growth rate as in the
CRTC bags, it is theoretically possible to expand 109 levels of
CD4+ T cells by general tissue culture method if we use
hundreds of culture plates and huge volumes of culture
medium. As shown in Figure 3, we demonstrate that 109
levels of CD4+ T cells can be expanded using a simple
CRTC culture bag system without changing medium. Our
established large-scale culture system, which consists of initial
culture using 96 well plates and late culture using the CRTC
bag, yielded a 3000 fold increase in cell number within 16
days of culture. Therefore, it is possible to obtain 1010
isolated CD4+ T cells in less than 20-day culture. We believe
that our established culture system is the simplest method for
the large-scale expansion of CD4+ helper/killer T cells. In
this paper, we showed four representative results using CD4+
T cells isolated from tumour patients. Generally, tumour-
bearing hosts reveal suppressed immune responses (Burgar et
al., 1984), whereas the separated CD4+ T cells from tumour
patients showed the same level of proliferative responses to
immobilised OKT-3 plus rIL-2 as CD4+ T cells isolated from
healthy donors (Nishimura et al., 1992a). Actually, CD4+ T
cells obtained from both tumour patients and healthy donors
showed the same growth curve in CRTC bags (data not
shown).
As shown in Table I and Figure 4, the CD4+ T cells
expanded in CRTC bag also showed both IL-2 producing
activity and OKT-3 mAb-mediated cytotoxicity. Triggering
of the expanded CD4+ T cells through CD3 molecule
stimulated both helper and killer functions. Therefore, if we
can target the CD4+ helper/killer cells to tumour cells using
anti-CD3 x anti-tumour bispecific antibody, the targeted
CD4+ T cells act as both killer and IL-2 producer at tumour
local site. As shown in Figure 5, CD4+ helper/killer cells
expanded by our established methods were specifically
targeted to c-erbB-2 positive tumour cell lines in vitro using
anti-CD3 x anti-c-erbB-2 BsAb. We have an evidence that
CD4+ helper/killer cells showed a strong therapeutic efficacy
against human colon cancer cells implanted into nude mice
by combination with BsAb (Nishimura et al., 1992b). Recent
results demonstrated that CD4+ tumour infiltrating lympho-
cytes were specifically targeted to tumour site compared with
LAK cells (Grimm et al., 1991). Several animal experiments
also demonstrated that adoptive tumour immunotherapy
using CD4+ T cells was effective (Bookman et al., 1987). The
therapeutic advantage of CD4+ helper/killer cells is that they
may function both as effector cells and helper cells at local
site of tumour. We believe that our established simple
method for the large-scale culture of CD4+ helper/killer will
be available for new trials of adoptive immunotherapy
(helper/killer therapy).
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